GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Establishment Labs Holdings Inc (NAS:ESTA) » Definitions » Sloan Ratio %

Establishment Labs Holdings (Establishment Labs Holdings) Sloan Ratio % : 12.86% (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Establishment Labs Holdings Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Establishment Labs Holdings's Sloan Ratio for the quarter that ended in Dec. 2023 was 12.86%.

As of Dec. 2023, Establishment Labs Holdings has a Sloan Ratio of 12.86%, indicating there is a warning stage of accrual build up.


Establishment Labs Holdings Sloan Ratio % Historical Data

The historical data trend for Establishment Labs Holdings's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Establishment Labs Holdings Sloan Ratio % Chart

Establishment Labs Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Sloan Ratio %
Get a 7-Day Free Trial -0.34 -12.82 -4.62 5.57 12.86

Establishment Labs Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.57 9.58 18.42 19.67 12.86

Competitive Comparison of Establishment Labs Holdings's Sloan Ratio %

For the Medical Devices subindustry, Establishment Labs Holdings's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Establishment Labs Holdings's Sloan Ratio % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Establishment Labs Holdings's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Establishment Labs Holdings's Sloan Ratio % falls into.



Establishment Labs Holdings Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Establishment Labs Holdings's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (A: Dec. 2023 )-Cash Flow from Operations (A: Dec. 2023 )
-Cash Flow from Investing (A: Dec. 2023 ))/Total Assets (A: Dec. 2023 )
=(-78.502--88.513
--24.547)/268.641
=12.86%

Establishment Labs Holdings's Sloan Ratio for the quarter that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Dec. 2023 )
=(-78.502--88.513
--24.547)/268.641
=12.86%

Establishment Labs Holdings's Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was -11.942 (Mar. 2023 ) + -16.745 (Jun. 2023 ) + -29.273 (Sep. 2023 ) + -20.542 (Dec. 2023 ) = $-78.5 Mil.
Establishment Labs Holdings's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2023 was -20.614 (Mar. 2023 ) + -28.24 (Jun. 2023 ) + -31.511 (Sep. 2023 ) + -8.148 (Dec. 2023 ) = $-88.5 Mil.
Establishment Labs Holdings's Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 was -4.278 (Mar. 2023 ) + -9.049 (Jun. 2023 ) + -6.6 (Sep. 2023 ) + -4.62 (Dec. 2023 ) = $-24.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Establishment Labs Holdings  (NAS:ESTA) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Dec. 2023, Establishment Labs Holdings has a Sloan Ratio of 12.86%, indicating there is a warning stage of accrual build up.


Establishment Labs Holdings Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Establishment Labs Holdings's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Establishment Labs Holdings (Establishment Labs Holdings) Business Description

Traded in Other Exchanges
Address
Coyol Free Zone, Building B15 and 25, Alajuela, CRI
Establishment Labs Holdings Inc is a medical technology company engaged in offering medical devices and aesthetic products. It is involved in designing, manufacturing, and marketing silicone-filled breast and body shaping implants. The company markets its products under Motiva implants Brand. It distributes its products to medical distributors; and physicians, hospitals, and clinics in the form of direct sales. Its geographical segments are Europe, Latin America, Asia-Pacific/Middle East, and Others.
Executives
Nicholas Sheridan Lewin director, 10 percent owner 3 WEST 57TH ST., 8TH FLOOR, NEW YORK NY 10019
Raj Denhoy officer: Chief Financial Officer C/O MOTIVA USA, LLC, 16192 COASTAL HIGHWAY, LEWES DE 19958
Dennis E Condon director 811 ALSTON RD, SANTA BARBARA CA 93108
Leslie Gillin director C/O MOTIVA USA, LLC, 16192 COASTAL HIGHWAY, LEWES DE 19958
Paul D. Rodio officer: Chief Operating Officer C/O MOTIVA USA LLC, 16192 COASTAL HIGHWAY, LEWES DE 19958
Samuel Ross Mansbach other: GC & Chief Compliance Officer C/O MOTIVA USA LLC, 16192 COASTAL HIGHWAY, LEWES DE 19958
Jw Asset Management, Llc 10 percent owner, other: See Footnote(1) 1051 N VENETIAN DRIVE, MIAMI BEACH FL 33139
Bryan Slotkin director C/O MOTIVA USA,.LLC, 16192 COASTAL HIGHWAY, LEWES DE 19958
Ann Custin director C/O MOTIVA USA, LLC, 16192 COASTAL HIGHWAY, LEWES DE 19958
Edward J Schutter director C/O FIRST HORIZON PHARMACEUTICAL CORP, 6195 SHILOH ROAD, ALPHARETTA GA 30005
Lisa Gersh director C/O HASBRO, INC., 1011 NEWPORT AVENUE, PAWTUCKET RI 02861
Mezerville Roberto De officer: Chief Technology Officer C/O MOTIVA USA LLC, 16192 COASTAL HIGHWAY, LEWES DE 19958
Renee Gaeta officer: Chief Financial Officer C/O MOTIVA USA LLC, 16192 COASTAL HIGHWAY, LEWES DE 19958
Pratip Dastidar officer: Head of Global Operations 150 PEABODY PLACE, MEMPHIS TN 38103
Santos Salvador Dada officer: Chief Operating Officer C/O MOTIVA USA LLC, 16192 COASTAL HIGHWAY, LEWES DE 19958